BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Immune Response BioPharma Announces Formulation Changes to Blockbuster RA Drug RAVAX


6/25/2012 10:56:09 AM

PRLog (Press Release) - Jun 25, 2012 - Immune Response BioPharma, Inc. Today, June 25th 2012, Announces Formulation Changes to Blockbuster RA Drug RAVAX Adds 4th Peptide for Potent RA Vaccine.

IRBP recognizes the need for safer and more tolerable yet effective Rheumatoid Arthritis treatments and adds a fourth TCR Poly-Peptide VB 12.1 to the RAVAX vaccine formulation, as it encompasses over 66% of patient gene types with RA. One of out five patient samples sequenced represented VB 12.1 thus we will add this important polypeptide; Human VB 12.1 DGYSVSRSKTEDFLL 66.7% will help us tweak the vaccine to show greater efficacy in the clinic. The new RAVAX encompasses Poly-Peptides BV 3, BV 14, BV 17 & BV 12.1.

IRBP believes RAVAX is a first in class and best in class Rheumatoid Arthritis drug that can become treatment of choice for RA patients with under 10 years of diagnosed RA disease. "We are excited about the potential for RAVAX and our newly announced Phase 3 head to head clinical trial RAVAX vs. Humira or Rituxan coupled with Estrogen as 70% of patients are women. IRBP expects improved results showing RAVAX can become a blockbuster treatment for RA. We are actively seeking a funding partner to drive this unique and wonderful treatment to the finish line and FDA approval" IRBP CEO Mr. David Buswell

Immune Response BioPharma, Inc. maybe found on the Worldwide Web @ www.immuneresponsebiopharma.com

Immune Response BioPharma, Inc. develops lifesaving drugs and therapeutic vaccines in the auto-immune, infectious disease areas. The company's proprietary pipeline includes first in class treatments Remune for AIDS, NeuroVax for MS, RAVAX for RA and Sepsicillin for Sepsis Shock. Immune Response BioPharma, Inc. was incorporated in 2011 and is based in New York, New York.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->